Category Archives: – Biotech

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry

September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking

Posted in - Biotech, - Pharma, Congress, FDA | Leave a comment

Actavis 1000% drug price hike: a case for healthcare reform

Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising

Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease | Leave a comment

The PCSK9 LDL drugs do not cut heart risk in half

March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data

Posted in - Biotech, - Opinion, Cardiac surgery, Cardiology, Primary care medicine | Leave a comment

Google wants your medical records

December 19, 2013- Interviewed by Steven E. Greer, MD In Part 3 of our interview with Robert Klitzman, MD, ethics professor at Columbia University,

Posted in - Biotech, - Policy, Columbia, FDA, Genetics | Leave a comment

New therapies for hepatitis C

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Super rapid acting insulin and inhaled insulin

September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University

Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Three-drug regimen for multiple myeloma

December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Steven Cummings, MD: The denosumab FREEDOM trial

August 11, 2009- Dr. Steven Cummings, director of the San Francisco Coordinating Center and faculty of UCSF, and

Posted in - Biotech, - NEJM, - Pharma, Diabetes and endocrinology, Obstetrics and Gynecology, Orthopedic surgery, Primary care medicine, Radiology, Spine surgery, Sports medicine, UC San Francisco | Leave a comment

Sundeep Khosla, MD discusses Amgen’s Denosumab

August 11, 2009- Sundeep Khosla of the Mayo Clinic who authored the NEJM editorial on Amgen’s denosumab

Posted in - Biotech, - Pharma, Mayo Clinic | Leave a comment